$Sivelestat sodium hydrate treatment for refractory Kawasaki disease$

Sivelestat sodium hydrate treatment for refractory Kawasaki disease

Background There is still no definite treatment for refractory Kawasaki disease (KD). In this pilot study, we evaluated the safety and efficacy of a new protocol consisting of sivelestat sodium hydrate (SSH) combined with additional i.v. immunoglobulin (IVIG) for KD resistant to initial IVIG therapy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatrics international 2019-05, Vol.61 (5), p.438-443
Hauptverfasser:	Ebata, Ryota, Yasukawa, Kumi, Nagai, Kazue, Saito, Yuko, Higashi, Kouji, Homma, Jun, Takada, Nobuyuki, Takechi, Fumie, Saito, Naoki, Kobayashi, Hironobu, Okunushi, Kentaro, Hamada, Hiromichi, Kohno, Yoichi, Hanaoka, Hideki, Shimojo, Naoki
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Child Child, Preschool Coronary artery coronary artery lesion Drug Therapy, Combination Female Fever Glycine - analogs & derivatives Glycine - therapeutic use Humans i.v. immunoglobulin Immunoglobulins Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use Infant Intravenous administration Kawasaki disease Lesions Male Medical treatment Mucocutaneous lymph node syndrome Mucocutaneous Lymph Node Syndrome - drug therapy neutrophil elastase Patients Pediatrics Pilot Projects Population studies Prospective Studies Safety Serine Proteinase Inhibitors - therapeutic use sivelestat sodium hydrate Sodium Sulfonamides - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!